Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorcaserin - Epygenix Therapeutics/University of California at San Fransisco

Next Previous
Drug Profile

Lorcaserin - Epygenix Therapeutics/University of California at San Fransisco

Alternative Names: EPX 200

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Epygenix Therapeutics; University of California at San Francisco; University of Colorado at Denver
  • Class Antiepileptic drugs; Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action 5-HT2C serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lennox-Gastaut syndrome
  • No development reported Dravet syndrome

Most Recent Events

  • 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Dravet-syndrome in USA
  • 30 Apr 2024 Epygenix Therapeutics has been acquired by Harmony Biosciences
  • 07 Sep 2022 Loracaserin receives Rare Paediatric Disease Designation from US FDA for Lennox-Gastaut Syndrome prior to September 2022 (Epygenix Therapeutics pipeline, September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top